Cambridge Enterprise portfolio companies Horizon Discovery and BlueGnome were both winners in the International Trade category of the...
Invalidating two biomarker patents could hold back the commercial development of personalized medicine
The $1,000 genome has arrived, providing the spur for personalised healthcare to move from theory to practice. Some existing examples of best practice and roadmaps for the future are pointing the way
Personalised healthcare promises long-term value. But how can Europe justify the upfront costs at a time of massive cuts in public spending?
A new study finds that investment in computer, communications and diagnostics technologies could drastically cut the long-term care costs for breast cancer and cardiovascular disease, through better use of patient screening and adherence to treatment.